Keay Nakae
Stock Analyst at Chardan Capital
(4.38)
# 371
Out of 5,124 analysts
253
Total ratings
43.44%
Success rate
26.52%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $3.74 | +220.86% | 19 | Dec 18, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $19.56 | +94.27% | 14 | Dec 9, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $66.39 | -9.62% | 22 | Dec 1, 2025 | |
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $1.23 | +103.25% | 7 | Nov 20, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 | $4.81 | +3.95% | 14 | Nov 14, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $5.80 | +141.38% | 22 | Nov 14, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $65.30 | +53.14% | 6 | Nov 13, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.15 | +381.93% | 13 | Nov 13, 2025 | |
| KRRO Korro Bio | Downgrades: Neutral | $25 → $7 | $8.01 | -12.61% | 4 | Nov 13, 2025 | |
| RNA Avidity Biosciences | Maintains: Neutral | $72 | $72.13 | -0.18% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $2.02 | +98.02% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $6.08 | +475.66% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $397.65 | +0.59% | 14 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $1.93 | +159.07% | 5 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $14.85 | -59.60% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $3.22 | +86.34% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.58 | +1,288.41% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.12 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $18.04 | -66.74% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $1.87 | +20,220.86% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $12.36 | +344.98% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $5.42 | +84.50% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $27.27 | +220.87% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.35 | +862.96% | 3 | Feb 9, 2021 |
SAB Biotherapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $3.74
Upside: +220.86%
Dyne Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $38
Current: $19.56
Upside: +94.27%
Arrowhead Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $60
Current: $66.39
Upside: -9.62%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.23
Upside: +103.25%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.81
Upside: +3.95%
Coya Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $14
Current: $5.80
Upside: +141.38%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $65.30
Upside: +53.14%
Orchestra BioMed Holdings
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.15
Upside: +381.93%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: $25 → $7
Current: $8.01
Upside: -12.61%
Avidity Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $72.13
Upside: -0.18%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $2.02
Upside: +98.02%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.08
Upside: +475.66%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $397.65
Upside: +0.59%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $1.93
Upside: +159.07%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $14.85
Upside: -59.60%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $3.22
Upside: +86.34%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.58
Upside: +1,288.41%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $18.04
Upside: -66.74%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $1.87
Upside: +20,220.86%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $12.36
Upside: +344.98%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $5.42
Upside: +84.50%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $27.27
Upside: +220.87%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.35
Upside: +862.96%